1	Metronomic	Metronomic	B-NP	JJ	O	2	NMOD	0
2	5-fluorouracil	5-fluorouracil	I-NP	NN	O	6	NMOD	0
3	,	,	I-NP	,	O	6	P	0
4	oxaliplatin	oxaliplatin	I-NP	NN	O	6	NMOD	0
5	and	and	I-NP	CC	O	6	NMOD	0
6	irinotecan	irinotecan	I-NP	NN	O	0	ROOT	0
7	in	in	B-PP	IN	O	6	NMOD	0
8	colorectal	colorectal	B-NP	JJ	O	9	NMOD	0
9	cancer	cancer	I-NP	NN	O	7	PMOD	0
10	.	.	O	.	O	6	P	0

1	Metronomic	Metronomic	B-NP	JJ	O	2	NMOD	0
2	chemotherapy	chemotherapy	I-NP	NN	O	17	SUB	0
3	(	(	O	(	O	16	DEP	0
4	the	the	B-NP	DT	O	12	NMOD	0
5	frequent	frequent	I-NP	JJ	O	12	NMOD	0
6	,	,	I-NP	,	O	12	P	0
7	long	long	I-NP	JJ	O	8	NMOD	0
8	term	term	I-NP	NN	O	12	NMOD	0
9	,	,	O	,	O	12	P	0
10	low	low	B-NP	JJ	O	12	NMOD	0
11	dose	dose	I-NP	NN	O	12	NMOD	0
12	administration	administration	I-NP	NN	O	16	DEP	0
13	of	of	B-PP	IN	O	12	NMOD	0
14	chemotherapeutic	chemotherapeutic	B-NP	JJ	O	15	NMOD	0
15	drugs	drug	I-NP	NNS	O	13	PMOD	0
16	)	)	O	)	O	2	NMOD	0
17	is	be	B-VP	VBZ	O	0	ROOT	0
18	a	a	B-NP	DT	O	20	NMOD	0
19	promising	promising	I-NP	JJ	O	20	NMOD	0
20	therapy	therapy	I-NP	NN	O	17	PRD	0
21	because	because	B-SBAR	IN	O	17	VMOD	0
22	it	it	B-NP	PRP	O	23	SUB	0
23	enhances	enhance	B-VP	VBZ	O	21	SBAR	17	enhances
24	the	the	B-NP	DT	O	26	NMOD	0
25	anti-endothelial	anti-endothelial	I-NP	JJ	O	26	NMOD	0
26	activity	activity	I-NP	NN	O	23	OBJ	18	activity
27	of	of	B-PP	IN	O	26	NMOD	0
28	conventional	conventional	B-NP	JJ	O	29	NMOD	0
29	chemotherapeutics	chemotherapeutic	I-NP	NNS	O	27	PMOD	0
30	,	,	O	,	O	17	P	0
31	but	but	O	CC	O	30	AMOD	0
32	with	with	B-PP	IN	O	31	DEP	0
33	lower	low	B-NP	JJR	O	37	NMOD	0
34	or	or	I-NP	CC	O	37	NMOD	0
35	no	no	I-NP	DT	O	37	NMOD	0
36	toxic	toxic	I-NP	JJ	O	37	NMOD	0
37	effects	effect	I-NP	NNS	O	32	PMOD	0
38	compared	compare	B-VP	VBN	O	37	NMOD	0
39	to	to	B-PP	TO	O	38	PMOD	0
40	maximum	maximum	B-NP	JJ	O	43	NMOD	0
41	tolerated	tolerate	I-NP	VBN	O	43	NMOD	0
42	dose	dose	I-NP	NN	O	43	NMOD	0
43	administration	administration	I-NP	NN	O	39	PMOD	0
44	.	.	O	.	O	31	P	0

1	The	The	B-NP	DT	O	2	NMOD	0
2	aims	aim	I-NP	NNS	O	7	SUB	0
3	of	of	B-PP	IN	O	2	NMOD	0
4	the	the	B-NP	DT	O	6	NMOD	0
5	present	present	I-NP	JJ	O	6	NMOD	0
6	study	study	I-NP	NN	O	3	PMOD	0
7	were	be	B-VP	VBD	O	0	ROOT	0
8	to	to	I-VP	TO	O	9	VMOD	0
9	compare	compare	I-VP	VB	O	7	PRD	0
10	,	,	O	,	O	9	P	0
11	in	in	B-ADVP	FW	O	9	VMOD	0
12	vitro	vitro	I-ADVP	FW	O	11	AMOD	0
13	and	and	O	CC	O	11	AMOD	0
14	in	in	B-ADVP	FW	O	11	AMOD	0
15	vivo	vivo	I-ADVP	FW	O	14	AMOD	0
16	,	,	O	,	O	9	P	0
17	the	the	B-NP	DT	O	21	NMOD	0
18	antiangiogenic	antiangiogenic	I-NP	JJ	O	20	AMOD	3	angiogenic
19	and	and	I-NP	CC	O	20	AMOD	0
20	antitumor	antitumor	I-NP	JJ	O	21	NMOD	0
21	activities	activity	I-NP	NNS	O	34	NMOD	18	activities
22	of	of	B-PP	IN	O	21	NMOD	0
23	metronomic	metronomic	B-NP	JJ	O	24	NMOD	0
24	irinotecan	irinotecan	I-NP	NN	O	22	PMOD	0
25	(	(	O	(	O	27	DEP	0
26	CPT-11	CPT-11	B-NP	NN	B-protein	27	DEP	0
27	)	)	O	)	O	24	NMOD	0
28	,	,	O	,	O	34	P	0
29	oxaliplatin	oxaliplatin	B-NP	NN	O	34	NMOD	0
30	(	(	O	(	O	32	DEP	0
31	L-OHP	L-OHP	B-NP	NN	B-protein	32	DEP	0
32	)	)	O	)	O	29	NMOD	0
33	and	and	O	CC	O	34	NMOD	0
34	5-fluorouracil	5-fluorouracil	B-NP	NN	O	9	OBJ	0
35	(	(	O	(	O	37	DEP	0
36	5-FU	5-FU	B-NP	NN	O	37	DEP	0
37	)	)	O	)	O	34	NMOD	0
38	in	in	B-PP	IN	O	34	NMOD	0
39	colorectal	colorectal	B-NP	JJ	O	40	NMOD	0
40	cancer	cancer	I-NP	NN	O	38	PMOD	0
41	and	and	O	CC	O	9	VMOD	0
42	to	to	B-VP	TO	O	43	VMOD	0
43	investigate	investigate	I-VP	VB	O	9	VMOD	0
44	the	the	B-NP	DT	O	46	NMOD	0
45	metronomic	metronomic	I-NP	JJ	O	46	NMOD	0
46	combination	combination	I-NP	NN	O	43	OBJ	0
47	of	of	B-PP	IN	O	46	NMOD	0
48	these	these	B-NP	DT	O	49	NMOD	0
49	drugs	drug	I-NP	NNS	O	47	PMOD	0
50	.	.	O	.	O	7	P	0

1	In	In	B-NP	FW	O	2	AMOD	0
2	vitro	vitro	I-NP	FW	O	4	NMOD	0
3	cell	cell	I-NP	NN	O	4	NMOD	0
4	proliferation	proliferation	I-NP	NN	O	17	NMOD	1	proliferation
5	,	,	O	,	O	17	P	0
6	combination	combination	B-NP	NN	O	7	NMOD	0
7	studies	study	I-NP	NNS	O	12	NMOD	0
8	and	and	O	CC	O	12	NMOD	0
9	vascular	vascular	B-NP	JJ	B-protein	12	NMOD	0
10	endothelial	endothelial	I-NP	JJ	I-protein	12	NMOD	0
11	growth	growth	I-NP	NN	I-protein	12	NMOD	0
12	factor	factor	I-NP	NN	I-protein	17	NMOD	0
13	(	(	O	(	O	15	DEP	0
14	VEGF	VEGF	B-NP	NN	B-protein	15	DEP	0
15	)	)	O	)	O	12	NMOD	0
16	secretion	secretion	B-NP	NN	O	17	NMOD	14	secretion
17	analyses	analysis	I-NP	NNS	O	18	SUB	0
18	were	be	B-VP	VBD	O	0	ROOT	0
19	performed	perform	I-VP	VBN	O	18	VC	0
20	on	on	B-PP	IN	O	19	VMOD	0
21	endothelial	endothelial	O	JJ	O	31	NMOD	0
22	(	(	O	(	O	24	DEP	0
23	HMVEC-d	HMVEC-d	B-ADJP	JJ	O	24	DEP	0
24	)	)	O	)	O	21	NMOD	0
25	and	and	O	CC	O	31	NMOD	0
26	colorectal	colorectal	B-NP	JJ	B-cell_line	27	NMOD	0
27	cancer	cancer	I-NP	NN	I-cell_line	31	NMOD	0
28	(	(	O	(	I-cell_line	31	NMOD	0
29	HT-29	HT-29	B-NP	NN	I-cell_line	31	NMOD	0
30	)	)	O	)	I-cell_line	31	NMOD	0
31	cells	cell	B-NP	NNS	I-cell_line	44	NMOD	0
32	exposed	expose	B-VP	VBN	O	31	NMOD	19	exposed
33	for	for	B-PP	IN	O	32	VMOD	0
34	144	144	B-NP	CD	O	35	NMOD	0
35	h	h	I-NP	NN	O	33	PMOD	0
36	to	to	B-PP	TO	O	32	VMOD	0
37	metronomic	metronomic	B-NP	JJ	O	38	NMOD	0
38	concentrations	concentration	I-NP	NNS	O	36	PMOD	0
39	of	of	B-PP	IN	O	38	NMOD	0
40	SN-38	SN-38	B-NP	NN	B-protein	39	PMOD	0
41	,	,	O	,	O	44	P	0
42	the	the	B-NP	DT	O	44	NMOD	0
43	active	active	I-NP	JJ	O	44	NMOD	0
44	metabolite	metabolite	I-NP	NN	O	20	PMOD	0
45	of	of	B-PP	IN	O	44	NMOD	0
46	CPT-11	CPT-11	B-NP	NN	B-protein	50	NMOD	0
47	,	,	I-NP	,	O	50	P	0
48	L-OHP	L-OHP	I-NP	NN	B-protein	50	NMOD	0
49	and	and	I-NP	CC	O	50	NMOD	0
50	5-FU	5-FU	I-NP	NN	O	45	PMOD	0
51	.	.	O	.	O	18	P	0

1	HT-29	HT-29	B-NP	NN	O	6	NMOD	0
2	human	human	I-NP	JJ	O	6	NMOD	0
3	colorectal	colorectal	I-NP	JJ	O	6	NMOD	0
4	cancer	cancer	I-NP	NN	O	6	NMOD	0
5	xenograft	xenograft	I-NP	NN	O	6	NMOD	0
6	model	model	I-NP	NN	O	7	SUB	0
7	was	be	B-VP	VBD	O	18	VMOD	0
8	used	use	I-VP	VBN	O	7	VC	0
9	and	and	O	CC	O	18	VMOD	0
10	tumour	tumour	B-NP	NN	O	11	NMOD	0
11	growth	growth	I-NP	NN	O	17	NMOD	4	growth
12	,	,	O	,	O	17	P	0
13	microvessel	microvessel	B-NP	NN	O	14	NMOD	0
14	density	density	I-NP	NN	O	17	NMOD	0
15	and	and	O	CC	O	17	NMOD	0
16	VEGF	VEGF	B-NP	NN	O	17	NMOD	0
17	quantification	quantification	I-NP	NN	O	18	SUB	0
18	were	be	B-VP	VBD	O	0	ROOT	0
19	performed	perform	I-VP	VBN	O	18	VC	0
20	in	in	B-PP	IN	O	19	VMOD	0
21	tumours	tumour	B-NP	NNS	O	20	PMOD	0
22	after	after	B-SBAR	IN	O	18	VMOD	0
23	the	the	B-NP	DT	O	24	NMOD	0
24	administration	administration	I-NP	NN	O	22	PMOD	0
25	of	of	B-PP	IN	O	24	NMOD	0
26	metronomic	metronomic	B-NP	JJ	O	35	NMOD	0
27	CPT-11	CPT-11	I-NP	NN	B-protein	26	NMOD	0
28	,	,	O	,	O	26	P	0
29	L-OHP	L-OHP	B-NP	NN	B-protein	26	NMOD	0
30	,	,	O	,	O	35	P	0
31	5-FU	5-FU	B-NP	NN	O	35	NMOD	0
32	and	and	O	CC	O	35	NMOD	0
33	their	their	B-NP	PRP$	O	35	NMOD	0
34	simultaneous	simultaneous	I-NP	JJ	O	35	NMOD	0
35	combination	combination	I-NP	NN	O	25	PMOD	0
36	.	.	O	.	O	18	P	0

1	Low	Low	B-NP	JJ	O	2	NMOD	0
2	concentrations	concentration	I-NP	NNS	O	10	NMOD	0
3	of	of	B-PP	IN	O	2	NMOD	0
4	SN-38	SN-38	B-NP	NN	B-protein	3	PMOD	0
5	,	,	O	,	O	10	P	0
6	but	but	O	CC	O	10	NMOD	0
7	not	not	O	RB	O	6	DEP	0
8	5-FU	5-FU	B-NP	NN	O	10	NMOD	0
9	and	and	I-NP	CC	O	10	NMOD	0
10	L-OHP	L-OHP	I-NP	NN	B-protein	13	SUB	0
11	,	,	O	,	O	10	P	0
12	preferentially	preferentially	B-ADVP	RB	O	13	VMOD	0
13	inhibited	inhibit	B-VP	VBD	O	0	ROOT	18	inhibited
14	endothelial	endothelial	B-NP	JJ	B-cell_type	16	NMOD	0
15	cell	cell	I-NP	NN	I-cell_type	16	NMOD	0
16	proliferation	proliferation	I-NP	NN	O	13	OBJ	1	proliferation
17	.	.	O	.	O	13	P	0

1	Simultaneous	Simultaneous	B-NP	JJ	O	4	NMOD	0
2	and	and	I-NP	CC	O	4	NMOD	0
3	continuous	continuous	I-NP	JJ	O	4	NMOD	0
4	exposure	exposure	I-NP	NN	O	17	SUB	19	exposure
5	of	of	B-PP	IN	O	4	NMOD	0
6	HT-29	HT-29	B-NP	NN	B-protein	9	NMOD	0
7	and	and	I-NP	CC	O	9	NMOD	0
8	HMVEC-d	HMVEC-d	I-NP	NN	B-cell_line	9	NMOD	0
9	cells	cell	I-NP	NNS	I-cell_line	5	PMOD	0
10	to	to	B-PP	TO	O	4	NMOD	0
11	low	low	B-NP	JJ	O	13	NMOD	0
12	concentrations	concentration	I-NP	NNS	O	13	NMOD	0
13	SN-38+L-OHP+5-FU	SN-38+L-OHP+5-FU	I-NP	NN	O	10	PMOD	0
14	for	for	B-PP	IN	O	4	NMOD	0
15	144	144	B-NP	CD	O	16	NMOD	0
16	h	h	I-NP	NN	O	14	PMOD	0
17	showed	show	B-VP	VBD	O	0	ROOT	0
18	a	a	B-NP	DT	O	20	NMOD	0
19	strong	strong	I-NP	JJ	O	20	NMOD	0
20	antagonism	antagonism	I-NP	NN	O	25	NMOD	0
21	and	and	O	CC	O	25	NMOD	0
22	an	an	B-NP	DT	O	25	NMOD	0
23	unfavorable	unfavorable	I-NP	JJ	O	25	NMOD	0
24	dose-reduction	dose-reduction	I-NP	NN	O	25	NMOD	0
25	index	index	I-NP	NN	O	17	OBJ	0
26	.	.	O	.	O	17	P	0

1	Moreover	Moreover	B-ADVP	RB	O	6	VMOD	0
2	,	,	O	,	O	6	P	0
3	the	the	B-NP	DT	O	5	NMOD	0
4	ternary	ternary	I-NP	JJ	O	5	NMOD	0
5	combination	combination	I-NP	NN	O	6	SUB	0
6	resulted	result	B-VP	VBD	O	0	ROOT	0
7	in	in	B-PP	IN	O	6	VMOD	0
8	a	a	B-NP	DT	O	10	NMOD	0
9	significant	significant	I-NP	JJ	O	10	NMOD	0
10	increase	increase	I-NP	NN	O	7	PMOD	17	increase
11	of	of	B-PP	IN	O	10	NMOD	0
12	VEGF	VEGF	B-NP	NN	B-protein	13	NMOD	0
13	secretion	secretion	I-NP	NN	O	11	PMOD	14	secretion
14	in	in	B-PP	IN	O	10	NMOD	0
15	HT-29	HT-29	B-NP	NN	B-cell_type	17	NMOD	0
16	cancer	cancer	I-NP	NN	I-cell_type	17	NMOD	0
17	cells	cell	I-NP	NNS	I-cell_type	14	PMOD	0
18	.	.	O	.	O	6	P	0

1	In	In	B-PP	IN	O	15	VMOD	0
2	a	a	B-NP	DT	O	6	NMOD	0
3	xenograft	xenograft	I-NP	NN	O	6	NMOD	0
4	model	model	I-NP	NN	O	6	NMOD	0
5	metronomic	metronomic	I-NP	JJ	O	6	NMOD	0
6	CPT-11	CPT-11	I-NP	NN	B-protein	1	PMOD	0
7	,	,	O	,	O	15	P	0
8	but	but	O	CC	O	12	NMOD	0
9	not	not	O	RB	O	8	DEP	0
10	5-FU	5-FU	B-NP	NN	O	12	NMOD	0
11	and	and	I-NP	CC	O	12	NMOD	0
12	L-OHP	L-OHP	I-NP	NN	B-protein	15	SUB	0
13	,	,	O	,	O	12	P	0
14	significantly	significantly	B-VP	RB	O	15	VMOD	0
15	inhibits	inhibit	I-VP	VBZ	O	0	ROOT	18	inhibits
16	HT-29	HT-29	B-NP	NN	O	18	NMOD	0
17	tumor	tumor	I-NP	NN	O	18	NMOD	0
18	growth	growth	I-NP	NN	O	21	NMOD	0
19	and	and	O	CC	O	21	NMOD	0
20	microvessel	microvessel	B-NP	NN	O	21	NMOD	0
21	density	density	I-NP	NN	O	15	OBJ	0
22	in	in	B-PP	IN	O	15	VMOD	0
23	the	the	B-NP	DT	O	24	NMOD	0
24	absence	absence	I-NP	NN	O	22	PMOD	0
25	of	of	B-PP	IN	O	24	NMOD	0
26	toxicity	toxicity	B-NP	NN	O	25	PMOD	0
27	.	.	O	.	O	15	P	0

1	On	On	B-PP	IN	O	8	VMOD	0
2	the	the	B-NP	DT	O	3	NMOD	0
3	contrary	contrary	I-NP	NN	O	1	PMOD	0
4	,	,	O	,	O	8	P	0
5	metronomic	metronomic	B-NP	JJ	O	7	NMOD	0
6	5-FU+L-OHP+CPT-11	5-FU+L-OHP+CPT-11	I-NP	NN	O	7	NMOD	0
7	therapy	therapy	I-NP	NN	O	8	SUB	19	therapy
8	did	do	B-VP	VBD	O	0	ROOT	0
9	not	not	I-VP	RB	O	8	VMOD	0
10	affect	affect	I-VP	VB	O	8	VC	16	affect
11	the	the	B-NP	DT	O	13	NMOD	0
12	microvascular	microvascular	I-NP	JJ	O	13	NMOD	0
13	count	count	I-NP	NN	O	10	OBJ	0
14	.	.	O	.	O	8	P	0

1	The	The	B-NP	DT	O	3	NMOD	0
2	metronomic	metronomic	I-NP	JJ	O	3	NMOD	0
3	concept	concept	I-NP	NN	O	4	SUB	0
4	might	might	B-VP	MD	O	0	ROOT	0
5	not	not	I-VP	RB	O	4	VMOD	0
6	universally	universally	I-VP	RB	O	4	VMOD	0
7	apply	apply	I-VP	VB	O	4	VC	0
8	to	to	B-PP	TO	O	7	VMOD	0
9	every	every	B-NP	DT	O	11	NMOD	0
10	cytotoxic	cytotoxic	I-NP	JJ	O	11	NMOD	0
11	drug	drug	I-NP	NN	O	18	NMOD	0
12	in	in	B-PP	IN	O	11	NMOD	0
13	colorectal	colorectal	B-NP	JJ	O	14	NMOD	0
14	cancer	cancer	I-NP	NN	O	12	PMOD	0
15	and	and	O	CC	O	18	NMOD	0
16	metronomic	metronomic	B-NP	JJ	O	18	NMOD	0
17	combination	combination	I-NP	NN	O	18	NMOD	0
18	regimens	regimen	I-NP	NNS	O	8	PMOD	0
19	should	should	B-VP	MD	O	4	VMOD	0
20	be	be	I-VP	VB	O	19	VC	0
21	used	use	I-VP	VBN	O	20	VC	0
22	with	with	B-PP	IN	O	21	VMOD	0
23	caution	caution	B-NP	NN	O	22	PMOD	0
24	.	.	O	.	O	4	P	0

